Shenzhen Hemogen Therapeutic Co., Ltd. (hereinafter referred to as “Hemogen”) has achieved a significant milestone in its international...

Thalassemia is a rare, inherited blood disorder caused by mutations in the genes involved in hemoglobin production that cause the body to produce less...

Recently, the Science and Technology Innovation Bureau of Yantian District, Shenzhen, issued the "Interim Measures for the Recognition and Manage...

On December 19, 2023, Hemogen Biotechnology Co., Ltd. (Hemogen), based in Shenzhen, successfully obtained the IND（investigational new drug) approval f...

On October 16th, during the visit of Indonesian President Joko Widodo to China and his attendance at the third Belt and Road International Cooperation...

Upon the invitation of KALBE, Indonesia's largest pharmaceutical company, and innovative biopharmaceutical company Etana Biotechnologies, Dr. Chao...

On October 10, 2023, CG Therapeutics Private Limited (CGT) and Hemogen HongKong Alpha Technology Limited, a subsidiary of Hemogen (Hong Kong), officia...

On July 18th, Dr. Chao Liu, CEO of Hemogen, Mr. Preecha Laohapongchana, Director of Xingtai Genetics, Dr. Apichat Asavamongkolkul, Dean of the Faculty...